NE58018
CAS:105462-23-5
NE58018 is a compound which has bioactive.
Formula:
C7H11NO7P2
Purity:
98%
Color and Shape:
Solid
Molecular weight:
283.11
Ref: TM-T19704
25mg | 1,432.00 € |
Estimated delivery in United States, on Friday 22 Nov 2024
Risedronate EP Impurity B (Risedronate USP Related Compound A)
Formula:
C7H11NO7P2
Color and Shape:
Off-White Solid
Molecular weight:
283.11
Ref: 4Z-R-055
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Friday 22 Nov 2024
[1-Hydroxy-2-(pyridin-2-yl)ethylidene]bis(phosphonic Acid) ([1-Hydroxy-2-(pyridin-2-yl)ethane-1,1-diyl]bis(phosphonic Acid))
Controlled ProductCAS:105462-23-5
Formula:
C7H11NO7P2
Color and Shape:
Neat
Molecular weight:
283.11
Ref: 86-MM0777.02-0025
25mg | 576.00 € |
Estimated delivery in United States, on Tuesday 26 Nov 2024
1-Hydroxy-2-(2-pyridinyl) Risedronate-d4 Hydrate (Major)
Controlled ProductCAS:105462-23-5
Applications 1-Hydroxy-2-(2-pyridinyl) Risedronate-d4 Hydrate is the isotope labelled analog of 1-Hydroxy-2-(2-pyridinyl) Risedronate. 1-Hydroxy-2-(2-pyridinyl) Risedronate is …
Formula:
C7D4H7NO7P2·H2O
Color and Shape:
Neat
Molecular weight:
305.152
Ref: TR-H952812
1mg | 260.00 € | ||
10mg | 1,754.00 € |
Estimated delivery in United States, on Thursday 2 Jan 2025
Risedronate Related Compound A
CAS:105462-23-5
Please enquire for more information about Risedronate Related Compound A including the price, delivery time …
Formula:
C7H11NO7P2
Purity:
Min. 95%
Molecular weight:
283.11 g/mol
Ref: 3D-FEA46223
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Thursday 2 Jan 2025
1-Hydroxy-2-(2-pyridinyl) Risedronate
CAS:105462-23-5
Applications 1-Hydroxy-2-(2-pyridinyl) Risedronate is an impurity in the synthesis of Risedronate (R521505), a pyridinyl biphosphonate …
Formula:
C7H11NO7P2
Color and Shape:
White to Off-White Solid
Molecular weight:
283.11
Ref: TR-H952810
5mg | Discontinued | Request information | |
50mg | Discontinued | Request information |